Sinecode syrup, 200 ml

Dry cough of any etiology (including whooping cough).

Suppression of cough in the pre- and postoperative period during surgery and bronchoscopy.

Inside, before meals.
Children from 3 to 6 years old - 5 ml 3 times a day;
6-12 years old - 10 ml 3 times a day;
12 years and older - 15 ml 3 times a day;
adults - 15 ml 4 times a day.
Use the measuring cap (supplied).

Active ingredient: Butamirate citrate - 1.5 mg / ml.

Excipients: sorbitol solution 70% m / m, glycerin (glycerol), sodium saccharin, benzoic acid, vanillin, ethanol 96% v / v., Sodium hydroxide 30% m / m, purified water.

Hypersensitivity to the components of the drug, children under 3 years of age (for children under 3 years of age, you can use Sinekod drops for oral administration).

Trade name: SINEKODЃ

International non-proprietary name: Butamirat.

Chemical structure: 2- [2- (diethylamino) -ethoxy] ethyl 2-phenylbutyrate citrate

Dosage form:

syrup.

Composition:

Active ingredient: Butamirate citrate - 1.5 mg / ml.

Excipients: sorbitol solution 70% m / m, glycerin (glycerol), sodium saccharin, benzoic acid, vanillin, ethanol 96% v / v., Sodium hydroxide 30% m / m, purified water.

Description: colorless transparent liquid with vanilla odor

Pharmacotherapeutic group:

central antitussive

ATX code: R05DB13.

Pharmacological properties

Butamirate, the active substance of the Sinekod drug, is a centrally acting antitussive agent, neither chemically nor pharmacologically related to opium alkaloids. It has an expectorant, moderate bronchodilatory and anti-inflammatory effect, has a direct effect on the cough center, improves spirometry (reduces airway resistance) and blood oxygenation.

Pharmacokinetics
Butamirate is rapidly and completely absorbed when taken orally. After taking 150 mg of butamirate, the maximum plasma concentration of the main metabolite (2-phenylbutyric acid) is reached after about 1.5 hours and is 6.4 ?g / ml. The half-life is 6 hours. When the drug is reappointed, its concentration in the blood remains linear and no cumulation is observed. Hydrolysis of butamirate, initially to 2-phenylbutyric acid and diethylaminoethoxyethanol, begins in the blood. These metabolites also have antitussive activity. Like butamirate, metabolites have an almost maximum (about 95%) degree of binding to plasma proteins, which causes, among other things, their long half-life from plasma. Metabolites are excreted mainly in the urine,moreover, acidic metabolites are largely associated with glucuronic acid.

Indications for use

Dry cough of any etiology (including whooping cough).

Suppression of cough in the pre- and postoperative period during surgery and bronchoscopy.

Contraindications
Hypersensitivity to the components of the drug, children under 3 years of age (for children under 3 years of age, you can use Sinekod drops for oral administration).

Application during pregnancy and lactation

In studies conducted in animals, no adverse effects on the fetus were noted. No controlled studies have been conducted in pregnant women. In this regard, Sinekod should not be used in the first trimester of pregnancy. In the II and III trimesters, the use of Sinekod is possible taking into account the benefits to the mother and the potential risk to the fetus. Given the lack of data on the excretion of the active substance in breast milk, the appointment of Sinekod during lactation is not recommended.

Method of administration and dosage
Inside, before meals.
Children from 3 to 6 years old - 5 ml 3 times a day;
6-12 years old - 10 ml 3 times a day;
12 years and older - 15 ml 3 times a day;
adults - 15 ml 4 times a day.
Use the measuring cap (supplied).

Side effects
Skin rash, nausea, diarrhea, dizziness (frequency less than 1%), allergic reactions.

Overdose
Symptoms: drowsiness, nausea, vomiting, diarrhea, loss of balance and decreased blood pressure.

Treatment: activated charcoal, saline laxatives, maintaining the function of the cardiovascular and respiratory systems.

Interaction with other medicinal products
No drug interactions have been described for butamirate.

special instructions

The syrup contains saccharin and sorbitol as sweeteners, therefore it can be prescribed for patients with diabetes mellitus.

Release form

100 ml and 200 ml of syrup in dark glass vials with a polyethylene and polypropylene cap, equipped with a child tamper-resistant system and a polypropylene measuring cap. 1 bottle together with instructions for use is placed in a cardboard box.

Shelf life is
5 years. Do not use after the expiration date.

Storage conditions
At a temperature not exceeding 30 ? C, out of the reach of children.

Conditions of dispensing from pharmacies.
Without recipe.